Interestingly, while c-Kit mutations are rare in cutaneous melanoma, they have been reported in 14% of mucosal melanomas, making c-Kit inhibitors, such as imatinib, a possible target treatment for these tumors (11). This evidence concerns the gene KIT and mucositis.